Langerhans Cell Histiocytosis in Children: Literature Review
https://doi.org/10.15690/vsp.v22i1.2520
Abstract
Relevant information on Langerhans cell histiocytosis development and course in children is presented. The current concepts of disease pathogenesis, principles of its severity evaluation, patients stratification into risk groups, as well as of clinical course features are described. Modern approaches to the disease treatment via targeted therapy are summarized and analyzed.
About the Authors
Evgeniy A. Burtsev
Morozovskaya Children’s City Hospital
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared.
Gleb O. Bronin
Morozovskaya Children’s City Hospital
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Not declared.
References
1. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–1331. doi: https://doi.org/10.1182/BLOOD.2019000934
2. Minkov M. Evolu tion of treatment of children with Langerhans cell histio cytosis. Pediatria. Journal n.a. G.N. Speransky. 2021;100(3):107–120. (In Russ). doi: https://doi.org/10.24110/0031-403x-2021-100-3-107-120
3. Alston RD, Tatevossian RG, McNally RJQ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5): 555–560. doi: https://doi.org/10.1002/PBC.20884
4. Aricò M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173(5): 663–670. doi: https://doi.org/10.1111/BJH.13955
5. Han D, Li F, Yahya WH, et al. Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series. J Pers Med. 2022;12(7):1024. doi: https://doi.org/10.3390/jpm12071024
6. Liu H, Stiller CA, Crooks CJ, et al. Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. Br J Haematol. 2022; 199(5):728–738. doi: https://doi.org/10.1111/bjh.18459
7. Belova VYu, Spichak II. Langerhans cell histiocytosis in children of the chelyabinsk region (1995–2018): incidence, clinical forms, treatment programs, survival. Pediatric Bulletin of the Southern Urals. 2020;(1):59–65. (In Russ). doi: https://doi.org/10.34710/chel.2020.61.36.009
8. Ribeiro KB, Degar B, Antoneli CBG, et al. Ethnicity, race, and socioeconomic status influence incidence of langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–987. doi: https://doi.org/10.1002/PBC.25404
9. Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26(145):170070. doi: https://doi.org/10.1183/16000617.0070-2017
10. Ma J, Laird JH, Chau KW, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Med. 2019;8(1):58–66. doi: https://doi.org/10.1002/CAM4.1844
11. Bagnasco F, Zimmermann SY, Egeler RM, et al. Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. Eur J Cancer. 2022;172:138–145. doi: https://doi.org/10.1016/J.EJCA.2022.03.036
12. Feng C, Li Y, Ke H, et al. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol. 2021;11:631682. doi: https://doi.org/10.3389/FONC.2021.631682
13. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4(8):1374–1384. doi: https://doi.org/10.1371/JOURNAL.PMED.0040253
14. Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451–461. doi: https://doi.org/10.1111/PED.12380
15. Badalian-Very G, Vergilio J-A, Degar BA, et al. MYELOID NEOPLASIA Brief report Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: https://doi.org/10.1182/blood-2010-04-279083
16. Pakneshan S, Salajegheh A, Smith RA, Lam AKY. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–356. doi: https://doi.org/10.1097/PAT.0B013doi: E328360B61D
17. Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329–341. doi: https://doi.org/10.1158/2159-8290.CD-18-1321
18. Thevakumaran N, Lavoie H, Critton DA, et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol. 2015;22(1):37–43. doi: https://doi.org/10.1038/NSMB.2924
19. Brown NA, Furtado LV, Betz BL, et al. Brief Report MYELOID NEOPLASIA High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10): 1655–1658. doi: https://doi.org/10.1182/blood-2014-05
20. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activa ting ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20): 3152–3155. doi: https://doi.org/10.1182/BLOOD-2013-06-511139
21. Ali S, Bailey M, Stephens P, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight. 2017;2(3):e89473. doi: https://doi.org/10.1172/jci.insight.89473
22. Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):839–851. doi: https://doi.org/10.1016/J.HOC.2015.06.004
23. Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021;39(Suppl 1):15–23. doi: https://doi.org/10.1002/HON.2857
24. Berres M-L, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2014;169(1):3–13. doi: https://doi.org/10.1111/bjh.13247
25. Berres ML, Lim KPH, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: https://doi.org/10.1084/JEM.20130977
26. Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549(7672):389–393. doi: https://doi.org/10.1038/nature23672
27. McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124(12): 2607–2620. doi: https://doi.org/10.1002/CNCR.31348
28. Haupt R, Minkov M, Astigarraga I, et al. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. Pediatr Blood Cancer. 2013;60(2):175–184. doi: https://doi.org/10.1002/pbc.24367
29. Jezierska M, Stefanowicz J, Romanowicz G, et al. Langerhans cell histiocytosis in children — A disease with many faces. Recent advances in pathogenesis, diagnosticexaminations and treatment. Postepy Dermatol Alergol. 2018;35(1):6–17. doi: https://doi.org/10.5114/pdia.2017.67095
30. Khung S, Budzik JF, Amzallag-Bellenger E, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013; 4(5):569–579. doi: https://doi.org/10.1007/S13244-013-0271-7
31. Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35(2):103–115. doi: https://doi.org/10.1007/S00247-004-1262-0
32. Abdelaal AHK, Sedky M, Gohar S, et al. Skeletal involvement in children with Langerhans cell histiocytosis: healing, complications, and functional outcome. SICOT-J. 2020;6:28. doi: https://doi.org/10.1051/SICOTJ/2020024
33. Allen CE, Flores R, Rauch R, et al. Neurodegenerative Central Nervous System Langerhans Cell Histiocytosis and Coincident Hydrocephalus: Treated with Vincristine/Cytosine Arabinoside. Pediatr Blood Cancer. 2010;54(3):416–423. doi: https://doi.org/10.1002/PBC.22326
34. Luz J, Zweifel D, Hüllner M, et al. Oral manifestation of Langerhans cell histiocytosis: a case report. BMC Oral Health. 2018;18(1): 106. doi: https://doi.org/10.1186/S12903-018-0568-5
35. Lakatos K, Sterlich K, Pötschger U, et al. Langerhans Cell Histiocytosis of the Orbit: Spectrum of Clinical and Imaging Findings. J Pediatr. 2021;230:174–181.e1. doi: https://doi.org/10.1016/J.JPEDS.2020.10.056
36. Parikh SN, Desai VR, Gupta A, Anton CG. Langerhans Cell Histiocytosis of the Clavicle in a 13-Year-Old Boy. Case Rep Orthop. 2014;2014:510287. doi: https://doi.org/10.1155/2014/510287
37. Song YS, Lee IS, Yi JH, et al. Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients. Skeletal Radiol. 2011;40(11):1421–1426. doi: https://doi.org/10.1007/S00256-010-1078-Y 38. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S82–S89. doi: https://doi.org/10.1016/J.BBMT.2009.11.014
38. Morren MA, Vanden Broecke K, Vangeebergen L, et al. Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study. Pediatr Blood Cancer. 2016;63(3):486–492. doi: https://doi.org/10.1002/PBC.25834
39. Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014;165(5):990–996. doi: https://doi.org/10.1016/J.JPEDS.2014.07.063
40. Battistella M, Fraitag S, Teillac DH, et al. Neonatal and early infantile cutaneous langerhans cell histiocytosis: comparison of self-regressive and non-self-regressive forms. Arch Dermatol. 2010;146(2):149–156. doi: https://doi.org/10.1001/ARCHDERMATOL.2009.360
41. Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71. doi: https://doi.org/10.1002/PBC.20479
42. Chander R, Jaykar K, Varghese B, et al. Pulmonary disease with striking nail involvement in a child. Pediatr Dermatol. 2008;25(6): 633–634. doi: https://doi.org/10.1111/J.1525-1470.2008.00788.X
43. Yadav SP, Kharya G, Mohan N, et al. Langerhans cell histiocytosis with digestive tract involvement. Pediatr Blood Cancer. 2010;55(4):748–753. doi: https://doi.org/10.1002/PBC.22663
44. Singhi AD, Montgomery EA. Gastrointestinal tract langerhans cell histiocytosis: A clinicopathologic study of 12 patients. Am J Surg Pathol. 2011;35(2):305–310. doi: https://doi.org/10.1097/PAS.0B013E31820654E4
45. Barclay M, Devaney R, Bhatt JM. Paediatric pulmonary Langerhans cell histiocytosis. Breathe (Sheff). 2020;16(2):200003. doi: https://doi.org/10.1183/20734735.0003-2020
46. Evseev DA, Kalinina II, Uskova NG, et al. The use of preventive pleurodesis in patient with Langerhans-cell histiocytosis with lung involvement: the case report and the review. Pediatric Hematology/Oncology and Immunopathology. 2018;17(3):74–80. (In Russ). doi: https://doi.org/10.24287/1726-1708-2018-17-3-74-80
47. Ronceray L, Pötschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome. J Pediatr. 2012;161(1):129–133.e1–3. doi: https://doi.org/10.1016/J.JPEDS.2011.12.035
48. Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26(5):351–356. doi: https://doi.org/10.1016/J.EJIM.2015.04.001
49. Bano S, Chaudhary V, Narula MK, et al. Pulmonary Langerhans cell histiocytosis in children: a spectrum of radiologic findings. Eur J Radiol. 2014;83(1):47–56. doi: https://doi.org/10.1016/J.EJRAD.2013.04.044
50. Abba ME, Żegleń S, Łącka M, et al. Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemotherapy With Cladribine: A Case Report. Transplant Proc. 2022;54(4): 1177–1179. doi: https://doi.org/10.1016/J.TRANSPROCEED.2022.02.037
51. Nezelof C, Frileux‐Herbet F, Cronier‐Sachot J. Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer. 1979;44(5):1824–1838. doi: https://doi.org/10.1002/1097-0142(197911)44:53.0.co;2-j
52. Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999;16(5):377–385. doi: https://doi.org/10.1080/088800199276921
53. Minkov M, Pötschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;49(5):694–698. doi: https://doi.org/10.1002/PBC.21227
54. Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13(9):1309–1322. doi: https://doi.org/10.1517/14656566.2012.688028
55. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocy tosis. Med Pediatr Oncol. 2002;38(3):178–182. doi: https://doi.org/10.1002/MPO.1306
56. Yi X, Han T, Zai H, et al. Liver involvement of Langerhans’ cell histiocytosis in children. Int J Clin Exp Med. 2015;8(5):7098. 58. Grana N. Langerhans cell histiocytosis. Cancer Control. 2014; 21(4):328–334. doi: https://doi.org/10.1177/107327481402100409
57. Hong L, Sun G, Peng L, et al. Solated Langerhans cell histiocytosis of the spleen: A case report. Medicine (Baltimore). 2018;97(38): e12378. doi: https://doi.org/10.1097/MD.0000000000012378
58. Edelweiss M, Medeiros LJ, Suster S, Moran CA. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007; 38(10):1463–1469. doi: https://doi.org/10.1016/J.HUMPATH. 2007.03.015
59. Yeh EA, Greenberg J, Abla O, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018;65(1). doi: https://doi.org/10.1002/PBC.26784
60. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881. e1. doi: https://doi.org/10.1016/J.JPEDS.2010.03.001
61. Crois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233. doi: https://doi.org/10.1002/PBC.20425
62. Nanduri VR, Bareille P, Pritchard J, Stanhope R. Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol (Oxf). 2000;53(4):509–515. doi: https://doi.org/10.1046/J.1365-2265.2000.01125.X
63. Chaudhary V, Bano S, Aggarwal R, et al. Neuroimaging of Langerhans cell histiocytosis: a radiological review. Jpn J Radiol. 2013;31(12):786–796. doi: https://doi.org/10.1007/S11604-013-0254-0
64. Gabbay LB, Leite C da C, Andriola RS, et al. Histiocytosis: a review focusing on neuroimaging findings. Arq Neuropsiquiatr. 2014;72(7):548–558. doi: https://doi.org/10.1590/0004-282X20140063
65. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–734. doi: https://doi.org/10.1067/mpd.2001.111331
66. Gadner H, Grois N, Pötschger U, et al. Improved outcome in multi system Langerhans cell histiocytosis is associated with therapy in ten sification. Blood. 2008;111(5):2556–2562. doi: https://doi.org/10.1182/blood-2007-08-106211
67. Grois N, Prayer D, Prosch H, Lassmann H. Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain. 2005;128 (Pt 4):829–838. doi: https://doi.org/10.1093/BRAIN/AWH403
68. Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study. Klin Padiatr. 1987;199(3):173–182. doi: https://doi.org/10.1055/s-2008-1026785
69. Ceci A, De Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X ’83 study. Med Pediatr Oncol. 1993;21(4):259–264. doi: https://doi.org/10.1002/MPO.2950210405
70. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014. doi: https://doi.org/10.1182/blood-2012-09
71. Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13(2):75–86. doi: https://doi.org/10.2165/11538540-000000000-00000
72. Héritier S, Jehanne M, Leverger G, et al Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis JAMA Oncol. 2015;1(6):836–838. doi: https://doi.org/10.1001/jamaoncol.2015.0736
73. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31): 2857–2865. doi: https://doi.org/10.1200/JCO.19.00456
74. Evseev D, Kalinina I, Raykina E, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cellfree circulating DNA. Int J Hematol. 2021;114(6):725–734. doi: https://doi.org/10.1007/s12185-021-03205-8
75. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms HHS Public Access. Nature. 2019;567:521–4. doi: https://doi.org/10.1038/s41586-019-1012-y
76. Burtsev EA, Bronin GO. MEK-inhibitors in treatment of Langerhans cell histiocytosis. Russian Journal of Pediatric Hematology and Oncology. 2022;9(3):42–47. (In Russ). doi: https://doi.org/10.21682/2311-1267-2022-9-3-42-47
77. Awada G, Seremet T, Fostier K, et al. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. Blood Adv. 2018;2(16):2156–2158. doi: https://doi.org/10.1182/BLOODADVANCES.2018021782
78. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–79. doi: https://doi.org/10.1002/PBC.21225
79. Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009;52(5):555–556. doi: https://doi.org/10.1002/PBC.21924
80. Abla O, Palmert MR. Reversal of LCH-related diabetes insipidus and reappearance of posterior pituitary bright spot with low-dose chemotherapy. Pediatr Blood Cancer. 2012;59(1):201–202. doi: https://doi.org/10.1002/PBC.24061
81. Imashuku S, Okazaki N, Nakayama M, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer. 2008;50(2):308–311. doi: https://doi.org/10.1002/PBC.21259
82. Gavhed D, Laurencikas E, Åkefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr. 2011;100(7):e36–e39. doi: https://doi.org/10.1111/J.1651-2227.2010.02125.X
83. Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a pros pective pilot study. Pediatr Blood Cancer. 2004;43(1):55–58. doi: https://doi.org/10.1002/PBC.20040
84. Euskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflammation. 2015;2(2):e78. doi: https://doi.org/10.1212/NXI.0000000000000078
85. Sveijer M, Von Bahr Greenwood T, Jädersten M, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198(4): 721–728. doi: https://doi.org/10.1111/bjh.18247
86. Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233–42. doi: https://doi.org/10.1080/14656566.2018.1429405
87. Volkova EN, Bronin GO, Vysotskaya TA, et al. Rezul’taty retrospektivnogo monotsentrovogo issledovaniya gistiotsitoza iz kletok langergansa u detei. Pediatria. Journal n.a. G.N. Speransky. 2009;87(4):33–40. (In Russ).
88. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society — Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–444. doi: https://doi.org/10.1002/PBC.20021
89. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996;14(7): 2073–2082. doi: https://doi.org/10.1200/JCO.1996.14.7.2073
90. Gurieva OD, Valiev TT, Pavlovskaya AI. Histiocytic neoplasms: modern aspects of pathogenesis, classification, diagnosis and treatment. Oncohematology. 2022;17(1):10–25. (In Russ). doi: https://doi.org/10.17650/1818
91. Chow TW, Leung WK, Cheng FWT, et al. Late outcomes in children with Langerhans cell histiocytosis. Arch Dis Child. 2017;102(9):830– 835. doi: https://doi.org/10.1136/ARCHDISCHILD-2016-312185
92. Rigaud C, Barkaoui MA, Thomas C, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–898. doi: https://doi.org/10.1111/BJH.14140
93. Di Iorgi N, Allegri AEM, Napoli F, et al. Central diabetes insipidus in children and young adults: etiological diagnosis and long-term outcome of idiopathic cases. J Clin Endocrinol Metab. 2014;99(4):1264–1272. doi: https://doi.org/10.1210/JC.2013-3724
94. Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans’ cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998;46(1-2):109–115. doi: https://doi.org/10.1016/S0165-5876(98)00116-5
Review
For citations:
Burtsev E.A., Bronin G.O. Langerhans Cell Histiocytosis in Children: Literature Review. Current Pediatrics. 2023;22(1):13-22. (In Russ.) https://doi.org/10.15690/vsp.v22i1.2520
Views:
889
Email this article 
